Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip™

Elisabet Cuàys, Estibaliz Olano-Martn, Olha Khymenets, Lorena Hernández, Laia Jofre-Monseny, Laura Grandoso, Diego Tejedor, Antonio Martnez, Maíg Farré, Rafael De La Torre

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)


Aims: Differences in adverse drug reactions can be explained by genetic variations, especially if they determine the expression of certain protein effectors and/or drug-metabolizing enzymes. Over the last decade, several tests screening for the most frequent polymorphisms in drug-metabolizing enzymes have been marketed for research and diagnostic purposes. The aim of this study was to assess the suitability of PHARMAchip™ for the genotyping of polymorphisms of genes associated with drug metabolism and response as an alternative to Jurilab Ltds DrugMEt® Test. Materials & methods: In this observational study, performed using 100 previously genotyped DNA samples, we report on common genes included in the two different tests examined: the former DrugMEt test and the recently introduced PHARMAchip test. Results & conclusion: Although these tests are based on different methodological approaches, we have found a high concordance of results between both methods. Some of the discrepancies between tests were related to allelic variants not monitored in a particular microarray and the quality of the genomic DNA used. © 2010 Future Medicine Ltd.
Original languageEnglish
Pages (from-to)257-266
Issue number2
Publication statusPublished - 1 Feb 2010


  • CYP2D6
  • CYP3A5
  • DNA array
  • NAT2
  • PHARMAchip ™
  • Pharmacogenetics


Dive into the research topics of 'Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip™'. Together they form a unique fingerprint.

Cite this